CRISPR Therapeutics (CRSP): ARK's Stock Stories

A few misplaced amino acids in the hemoglobin protein can cause a lifetime of pain, organ damage, and emergency transfusions. For 30 years, the standard of care for these cickle cell anemia patients was hydroxyura, a drug approved in 1998 that manages symptoms without correcting the underlying genetic defect. In December 2023, the FDA approved a therapy that acts as a functional cure for this disorder.Crisper Therapeutics built Casvy, the first commercially approved crisper edited medicine. The treatment ex ...